Tazemetostat Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 20 mg
Reference Brands: Tazverik (USA/EU)
Category:
Oncology Cancer Care
Tazemetostat is available in Tablets
and strengths such as 20 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tazemetostat is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tazemetostat can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tazemetostat is an oral anticancer medicine sold under the brand name Tazverik and is used for the treatment of certain rare and advanced cancers. It is specifically indicated for adults and adolescents aged 16 years and older with metastatic or locally advanced epithelioid sarcoma who are not eligible for complete surgical removal of the tumor. This type of sarcoma is a rare soft tissue cancer that can be difficult to treat when surgery is not fully possible.
Tazemetostat works as a selective inhibitor of enhancer of zeste homolog 2 (EZH2), an enzyme involved in regulating gene expression through epigenetic modification. In some cancers, EZH2 activity is abnormally increased and contributes to tumor growth and progression. By blocking EZH2, tazemetostat helps slow or stop the growth of cancer cells. In addition to epithelioid sarcoma, it is also used in certain patients with relapsed or refractory follicular lymphoma with specific genetic features. Its targeted mechanism offers a precision-based treatment option for eligible patients.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing